Every Form 4 that United States Antimony Corporation (UAMY) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow UAMY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full UAMY filings page.
UNITED STATES ANTIMONY CORP (UAMY) director and officer Lloyd Bardswich purchased 20,000 shares of common stock on September 1, 2026 in a transaction reported as a purchase in the open market or a private transaction at $4.635 per share. Following this buy, he directly holds 932,881 shares of UAMY common stock. No Rule 10b5-1 trading plan is reported for this transaction.
UNITED STATES ANTIMONY CORP (UAMY) director Joseph A. Carrabba reported an open-market purchase of 21,300 shares of common stock on 2026-09-01 at an average price of $4.72 per share. Following this transaction, he directly owns 198,401 shares of UAMY common stock.
UNITED STATES ANTIMONY CORP (UAMY) director Blaise A. Aguirre reported a purchase of 1,400 shares of Common Stock on 2026-08-31 in an open-market or private transaction at $5.035 per share. Following this transaction, Aguirre directly holds 878,092 shares of UAMY common stock.
UNITED STATES ANTIMONY CORP (UAMY) director and Chairman & CEO Gary C. Evans purchased common stock in an open-market or private transaction. On 2026-08-28, he bought 20,000 shares of common stock at $4.92 per share, bringing his directly held position to 2,590,028 shares after the transaction.
UNITED STATES ANTIMONY CORP director Jon R. Marinelli bought shares in the company. On the reported date, he made an open-market purchase of 12,500 shares of Common Stock at a weighted average price of $7.45 per share.
After this transaction, Marinelli directly owned 12,500 shares. According to the filing, the shares were purchased in multiple trades at prices ranging from $7.41 to $7.50 per share.
UNITED STATES ANTIMONY CORP senior vice president and chief financial officer Richard R. Isaak reported a disposition of 100,000 shares of common stock back to the company. This was a "Disposition to issuer" at $9.75 per share. After this transaction, he directly holds 344,376 common shares, indicating he retains a substantial equity position.
UNITED STATES ANTIMONY CORP executive Melissa Pagen, President & COO of BRZ, reported a disposition of 89,004 shares of common stock on March 23, 2026. The weighted average price was $9.14 per share, with individual trades ranging from $9.05 to $9.26. After this transaction, she directly holds 44,825 shares of the company’s stock.
UNITED STATES ANTIMONY CORP director and officer Lloyd Bardswich reported a disposition of 59,872 shares of Common Stock back to the issuer. The transaction, coded as a Disposition to issuer, was recorded at $8.98 per share. Following this transaction, Bardswich directly holds 877,483 shares of the company’s Common Stock.
UNITED STATES ANTIMONY CORP director Blaise A. Aguirre reported multiple dispositions of common stock back to the company. On March 31, 2026, he disposed of several blocks totaling 27,000 shares at prices between $8.20 and $8.26 per share, each coded as a “Disposition to issuer” (D). After these transactions, he directly held 845,754 shares of United States Antimony common stock.
UNITED STATES ANTIMONY CORP director and executive officer Lloyd Bardswich reported two dispositions of common stock back to the issuer. On March 26, 2026, he disposed of 46,674 shares at $9.34 per share, and on March 27, 2026, he disposed of 36,181 shares at $9.05 per share.
Across both transactions, a total of 82,855 common shares were returned to the company. Following these issuer dispositions, Bardswich directly holds 937,355 shares of UNITED STATES ANTIMONY CORP common stock, indicating he retains a substantial equity position after the reported activity.
UNITED STATES ANTIMONY CORP director Blaise A. Aguirre reported returning shares of common stock to the company. On March 24, 2026, he disposed of 20,000 shares at $9.16 per share, a transaction classified as a "Disposition to issuer".
On March 27, 2026, he reported two additional dispositions to the issuer of 6,339 shares at $8.78 per share and 5,373 shares at $8.77 per share. After these transactions, he directly held 872,754 shares of common stock, indicating that only a small portion of his overall position was returned to the company.
UNITED STATES ANTIMONY CORP granted equity awards to Chairman & CEO Gary C. Evans as part of compensation. He received a time-based restricted stock unit (RSU) award covering 304,524 shares of Common Stock under the Amended & Restated 2023 Equity Incentive Plan. One-third, or 101,508 shares, vest on January 15, 2026, with additional one-third portions vesting on January 15, 2027 and January 18, 2028, subject to continued service. He also received a stock option for 308,133 shares of Common Stock with a conversion or exercise price of $8.29 per share, which can vest upon meeting specified performance measures at any time during its 10-year term, also contingent on continued service. These are grant/award acquisitions, not open-market purchases or sales.
United States Antimony Corp granted equity awards to John C. Gustavsen, its President, Antimony Division. He received a restricted stock unit award covering 50,754 shares of Common Stock, vesting in three equal installments on January 15, 2026, January 15, 2027, and January 18, 2028, subject to continued service. He was also granted a stock option over 61.627 shares of Common Stock at an exercise price of $8.2900 per share, which vests upon achieving specified performance measures at any time during its 10-year term, also conditioned on continued service. These are compensation-related grants, not open-market purchases or sales.
UNITED STATES ANTIMONY CORP reported an insider transaction by its SVP and Chief Financial Officer, Richard R. Isaak. He disposed of a total of 83,334 shares of common stock back to the company in two issuer-related transactions, not open-market sales.
On March 25, he returned 30,000 shares at $10.00 per share, and on March 26, he returned 53,334 shares at $9.00 per share. Following these transactions, he directly holds 354,886 shares of common stock.
United States Antimony Corp Chairman and CEO Gary C. Evans reported four issuer dispositions of Common Stock on March 25, 2026, totaling 400,000 shares at prices between 9.76 and 9.88 per share. After these transactions, he directly owns 2,231,951 shares.
UNITED STATES ANTIMONY CORP executive Jeffrey Russell Fink, VP and General Manager of BRZ, reported several dispositions of common stock back to the company. On March 23 and 25, 2026, he transferred a total of 34,055 shares to the issuer at prices between $8.91 and $10.00 per share. After these transactions, he directly owned 108,656 shares of common stock, indicating he retains a substantial equity position.
United States Antimony Corp. reported new equity awards to officer Melissa Pagen, President & COO, BRZ, dated January 15, 2026. She received 40,603 restricted stock units (RSUs), which will vest in three equal installments of 13,535 shares on January 15, 2027, January 18, 2028, and January 19, 2029, subject to continued service. She was also granted stock options covering 61,627 shares of common stock at an exercise price of $8.29 per share. The options vest upon achievement of specified performance measures at any time during their 10‑year term, contingent on her continued service.
United States Antimony Corp. reported new equity awards to director and executive officer Lloyd Bardswich, who serves as Dir, EVP & Chief Mining Eng. On January 15, 2026, he received time-based restricted stock units covering 73,086 shares of common stock under the company’s Amended & Restated 2023 Equity Incentive Plan.
One-third of this RSU award, or 24,362 shares, will vest on January 15, 2026, with additional one-third portions vesting on January 15, 2027 and January 18, 2028, subject to continued service. On the same date, he was also granted stock options on 92,440 shares of common stock at an exercise price of $8.29 per share, which vest upon meeting specified performance measures during the 10-year term, also conditional on continued service.
United States Antimony Corp director Jon R. Marinelli reported receiving new equity awards under the company's Amended & Restated 2023 Equity Incentive Plan. On January 15, 2026, he was granted 1,659 shares of common stock underlying time-based restricted stock units (RSUs), with one-third, or 553 shares, scheduled to vest on January 15, 2027, and additional one-third tranches vesting on January 18, 2028 and January 16, 2029, subject to his continued service. He also received a stock option for 1,022 shares of common stock at an exercise price of $8.29 per share, vesting on the same three dates in equal installments of 341 shares, also conditioned on continued service.
United States Antimony Corp executive compensation update: VP and General Manager, BRZ, Jeffrey Russell Fink reported new equity awards tied to his role at the company. On January 15, 2026, he received restricted stock units covering 22,955 shares of common stock under the Amended & Restated 2023 Equity Incentive Plan. One-third, or 7,652 shares, will vest on January 15, 2027, and additional one-third portions will vest on January 18, 2028 and January 19, 2029, as long as he continues to serve the company.
He was also granted a stock option covering 40,054 shares of common stock at an exercise price of $8.29 per share. This option vests only if specified performance measures in the grant are achieved at any time during its 10-year term, again requiring continued service through any vesting date.
United States Antimony Corporation reported an equity compensation grant to its SVP and Chief Financial Officer, Richard R. Isaak. On January 15, 2026, he received restricted stock units covering 73,086 shares of common stock under the Amended & Restated 2023 Equity Incentive Plan. One-third, or 24,362 shares, will vest on January 15, 2026, with additional one-third installments vesting on January 15, 2027 and January 18, 2028, contingent on continued service. He was also granted a stock option over 82,169 shares of common stock with an exercise price of $8.29 per share. The option vests upon meeting specified performance measures at any time during its 10-year term, also subject to continued service.
United States Antimony Corp. granted equity awards to director John M. Keane as part of its Amended & Restated 2023 Equity Incentive Plan. On January 15, 2026, he received time-based restricted stock units representing 7,464 shares of common stock, vesting in three equal installments of 2,488 shares on January 15, 2027, January 18, 2028, and January 16, 2029, subject to continued service. He was also granted a time-based stock option for 4,597 shares at an exercise price of $8.29 per share, vesting in three installments of 1,533 shares on the same dates, also conditioned on continued service as a director.
United States Antimony Corp director Michael A. McManus Jr. reported equity awards under the company’s Amended & Restated 2023 Equity Incentive Plan. On January 15, 2026, he acquired 6,635 shares of common stock at $0 as part of a time-based restricted stock unit grant. These shares represent one-third of a larger 19,903-share RSU award, with the remaining portions scheduled to vest in equal tranches on January 15, 2027 and January 18, 2028, subject to his continued service.
He was also granted a stock option for 12,259 shares of common stock at an exercise price of $8.29 per share, vesting in three equal installments of 4,087 shares on January 15, 2027, January 18, 2028, and January 16, 2029, again contingent on continued service. Following these transactions, McManus beneficially owned 538,600 shares of common stock directly.
United States Antimony Corp. director Joseph A. Carrabba reported new equity awards and share ownership changes. On January 15, 2026, he acquired 6,635 shares of common stock at a price of $0, representing the first one-third tranche of a 19,903-share time-based restricted stock unit award under the Amended & Restated 2023 Equity Incentive Plan. After this transaction, he beneficially owned 112,702 shares of common stock directly.
On the same date, he was also granted a stock option covering 12,259 shares of common stock at an exercise price of $8.29 per share. The option is scheduled to vest in three equal installments of 4,087 shares each on January 15, 2027, January 18, 2028 and January 16, 2029, subject to his continued service through each vesting date.
United States Antimony Corp. director Blaise A. Aguirre reported new equity awards under the company’s Amended & Restated 2023 Equity Incentive Plan. On January 15, 2026, he acquired 6,635 shares of common stock at $0 as the first vesting tranche of a 19,903-share time-based restricted stock unit award. After this vesting, he beneficially owned 496,001 common shares directly.
On the same date, he was also granted a stock option for 12,259 shares with an exercise price of $8.29 per share. This option vests in three equal installments of 4,087 shares each on January 15, 2027, January 18, 2028, and January 16, 2029, subject to his continued service. These awards align his compensation more closely with the future performance of United States Antimony Corp.
United States Antimony Corp (UAMY) director and officer Lloyd Bardswich reported a sale of 40,000 shares of the company's common stock on 09/29/2025 at a price of $6.44 per share. After the sale the filing shows beneficial ownership listed as 594.047 (as reported). The Form 4 was signed by the reporting person on 10/04/2025. No derivative transactions or additional purchases were disclosed.
Jeffrey Russell Fink, an officer and director of United States Antimony Corp (UAMY), reported two open-market dispositions on 10/03/2025. The filing shows a sale of 2,833 shares at $8.16 and a sale of 8,000 shares at $8.12. After those transactions the reported beneficial ownership totals are listed as 64,000 shares and 56,000, respectively, held in a direct capacity. The Form 4 is signed by the reporting person and indicates the transactions were not reported as part of a 10b5-1 plan. The filing provides a straightforward record of insider selling activity without additional commentary or explanatory notes.
United States Antimony Corp (UAMY) director Michael A. McManus Jr. reported selling 50,000 shares of common stock on 10/01/2025 at a reported price of $7.316 per share. After the sale he beneficially owns 531,965 shares. The Form 4 was signed on 10/02/2025 and shows the transaction as a direct disposition by a director.
Jeffrey R. Fink, an officer and director of United States Antimony Corp (UAMY), reported the sale of 12,500 shares of the company's common stock on September 24, 2025 at a reported price of $7.87 per share. After the transaction he beneficially owned 66,833 shares. The Form 4 was signed on October 2, 2025. The filing discloses a straightforward open-market disposition by an insider and contains no derivative transactions or additional explanations.
Richard R. Isaak, Senior Vice President and Chief Financial Officer of United States Antimony Corp (UAMY), reported a sale of 50,000 shares of the company's common stock on 10/01/2025 at a price of $7 per share. Following the reported disposition, he beneficially owns 251,744 shares. The Form 4 was signed by Mr. Isaak on 10/01/2025.
Gary C. Evans, Chairman & CEO and a director of United States Antimony Corp (UAMY), reported a purchase of 100,000 shares of the company on 09/26/2025 at a price of $6.132 per share. Following the transaction, Mr. Evans beneficially owns 2,378,818 shares. The Form 4 was filed as a single reporting person filing and bears Mr. Evans' signature dated 09/26/2025.
Gary C. Evans, Chairman & CEO of United States Antimony Corp (UAMY), reported grants on 05/27/2025 consisting of 750,000 restricted stock units (RSUs) and a stock option covering 750,000 shares with an exercise price of $2.57. One-third of the RSU award (250,000 shares) vested on 05/27/2025 and the remaining two tranches vest on 05/27/2026 and 05/27/2027, subject to continued service and shareholder approval of the issuer’s Amended and Restated 2023 Equity Incentive Plan. The option award vests only upon meeting specified performance measures anytime during its 10-year term and is also subject to shareholder approval. The Form 4 was signed by Mr. Evans on 09/16/2025.
United States Antimony Corp (UAMY) insider award disclosure: Director and EVP Lloyd Bardswich was granted time-based restricted stock units totaling 180,000 shares and stock options covering 225,000 shares on 05/27/2025. The RSUs vest one-third on 05/27/2025 and the remainder in equal annual tranches through 05/27/2027, subject to continued service and shareholder approval of the company's Amended Restated 2023 Equity Incentive Plan. The options carry a $2.57 exercise price and vest upon achievement of specified performance measures at any time during their 10-year term, also subject to continued service and shareholder approval. The Form 4 reports these awards as beneficially owned following the transactions and is signed by Lloyd Joseph Bardswich on 09/18/2025.